| Literature DB >> 6118859 |
P J Whorwell, G M Whorwell, J Bamforth, D Colin Jones, P Down, A Edwards, A E Gent, P Golding, K R Gough, M D Hellier, P Isaacson, C A Loehry, G J Milton-Thompson, C L Smith, R P Waldram, R Wright.
Abstract
A double-blind controlled trial of the effect of sodium cromoglycate (SCG) in preventing relapse in ulcerative colitis has been completed in 100 subjects. In patients already taking sulphasalazine, SCG did not prove to be of any additional benefit. However, in patients not on any other maintenance therapy, the relapse rate was 40% for SCG as compared with 75% for placebo. A large study of the effect of SCG in patients intolerant of sulphasalazine is indicated.Entities:
Mesh：
Substances：
Year: 1981 PMID： 6118859 PMCID： PMC2424968 DOI： 10.1136/pgmj.57.669.436
Source DB: PubMed Journal: Postgrad Med J ISSN： 0032-5473 Impact factor: 2.401